<DOC>
	<DOCNO>NCT01261728</DOCNO>
	<brief_summary>The purpose study see get chemotherapy Gemcitabine Cisplatin four 21 day cycle total 12 week help shrink tumor undergo surgery kidney cancer .</brief_summary>
	<brief_title>Gemcitabine Cisplatin Neoadjuvant Chemotherapy Patients With High-Grade Upper Tract Urothelial Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically confirm highgrade upper tract transitional cell carcinoma MSKCC participate site and/or radiographically visible tumor stage T2T4a N0/X M0 disease positive selective urinary cytology . Hydronephrosis associate tumor image biopsy consider invasive definition . Medically appropriate candidate radical nephroureterectomy ureterectomy per MSKCC participate site attend urologic oncologist Karnofsky Performance Status ≥ 70 % Age ≥ 18 year age Required Initial Laboratory Values : Absolute neutrophil count ≥ 1500 cells/mm3 Platelets ≥ 100,000 cells/mm3 Hemoglobin ≥ 9.0g/dL Bilirubin ≤ 1.5 Aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤ 2.5 x ULN institution Alkaline phosphatase ≤ 2.5 x ULN institution Serum creatinine ≤ 1.5 mg/dL calculate creatinine clearance ≥ 55 If female childbearing potential , serum pregnancy test negative . Patients reproductive potential must use effective method avoid pregnancy duration trial . ml/min/1.73m2 use formula : CKD epi : GFR = 141 X min ( Scr/κ,1 ) α X max ( Scr/κ,1 ) 1.209 X 0.993Age X 1.018 [ female ] X 1.159 [ black ] Scr serum creatinine , k 0.7 female 0.9 male , 0.329 female 0.411 male , min indicate minimum Scr/k 1 , max indicate maximum Scr/k 1 . If female childbearing potential , serum pregnancy test negative . Patients reproductive potential must use effective method avoid pregnancy duration trial Concomitant bladder urothelial carcinoma acceptable organ confine surgically resectable . Presence carcinoma situ ( CIS ) Prior systemic chemotherapy ( prior intravesical therapy allow ) Prior radiation therapy bladder Evidence NYHA functional class III IV heart disease . Serious intercurrent medical psychiatric illness , include serious active infection . Preexisting sensory grade 3 neuropathy Major surgery radiation therapy &lt; 4 week start study treatment . Concomitant use investigational drug Any follow within 6 month prior study drug administration : myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident transient ischemic attack , pulmonary embolism . Ongoing cardiac dysrhythmias NCI CTCAE Version 4.0 grade ≥ 2 . Uncontrolled hypertension ( &gt; 150/100 mmHg despite optimal medical therapy ) . Known human immunodeficiency virus ( HIV ) acquire immunodeficiency syndrome ( AIDS ) relate illness active infection . Patients HIV evidence AIDS consider candidate . Concurrent treatment another clinical trial involve intervention may affect primary endpoint . Supportive care trial nontreatment trial , e.g . QOL , allow . Ongoing treatment therapeutic dos warfarin low molecular weight heparin ( low dose warfarin 2 mg po daily use subcutaneous low molecular weight heparin thromboembolic prophylaxis allow ) . Pregnancy breastfeed . Patients must surgically sterile postmenopausal , must agree use effective contraception period therapy . The definition effective contraception base judgment MSKCC participate site PI . Male patient must surgically sterile agree use effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Gemcitabine</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Bladder</keyword>
	<keyword>radical nephroureterectomy</keyword>
	<keyword>ureterectomy</keyword>
	<keyword>10-208</keyword>
</DOC>